FDA data Registry peer set 4 peers

Alternatives to infliximab

4 same-class SPL records vs infliximab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Remicade

TNF-Alpha Inhibitor (Biologic) Prescription 4 alternatives found

How to read a high-report FAERS peer set

infliximab ranks in the upper FAERS-volume third of the corpus (#25 of 524); 4 same-class peers are listed for field comparison only. Labeled indication field for infliximab: Inflectra treats Crohn's disease in adults and children (6+).

Top FAERS reaction fields for infliximab total 153,814 reports across 10 reactions, set beside adalimumab, certolizumab, etanercept. Counts are exposure-weighted submissions, not per-patient risk.

About infliximab

Inflectra is a medicine that blocks a protein called TNF. It is used to treat autoimmune diseases and reduce inflammation.

Used for: Inflectra treats Crohn's disease in adults and children (6+). It helps reduce symptoms and keep the disease under control. It also treats ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

4 TNF-Alpha Inhibitor (Biologic) peers (wide set)

Compare infliximab vs adalimumab side-by-side →

infliximab vs adalimumab & certolizumab · FAERS reaction fields

FAERS top-reaction field "Arthralgia" shows the widest count spread between infliximab and adalimumab, certolizumab, etanercept in this extract (31,186-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect infliximab adalimumabcertolizumabetanercept
Infusion Related Reaction 18,648 - - -
Condition Aggravated 18,301 - - 20,532
Rheumatoid Arthritis 18,136 35,573 - 46,175
Pain 18,107 49,062 - 43,004
Arthralgia 16,853 48,039 - 44,971
Fatigue 16,118 39,111 - 30,269
Rash 12,886 25,271 - 20,059
Nausea 11,872 27,102 - 19,211

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

infliximab FAERS volume vs class peers

FAERS volume band

infliximab is FAERS corpus rank #25 of 524 (high volume tercile). Top-reaction field total: 153,814.

Frequently Asked Questions

Where does infliximab sit in FAERS report volume vs TNF-Alpha Inhibitor (Biologic) peers?
infliximab ranks #25 of 524 drugs by FAERS top-reaction report volume (high volume tercile). Top-reaction fields total 153,814 submissions in this extract, exposure-weighted counts, not per-patient risk.

Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full infliximab profile →

Field note for infliximab: see also the generic vs brand label guide when reading Remicade SPL strings.